HCV spread among female incarcerated population and treatment pathways to viral elimination in Italian prison settings: clinical perspectives and medico legal aspects

Vito Fiore1*, Elena Rastrelli2, Giordano Madeddu1, Roberto Ranieri3, Andrea De Vito1, Ruggero Giuliani3, Giulio Di Mizio4, Matteo Bolcato5, Giuseppe De Matteis6, Anna Maria Ialungo2, Serena Dell’Isola2, Giulio Starnini2 and Sergio Babudieri1

Abstract

Background: Hepatitis C virus (HCV) infection is more frequent among incarcerated people than in general population. In the DAAs era, the short schedules and the low risk of adverse reactions, increased the number of HCV treatments. However, the most part of literature reports lack of incarcerated women inclusion in studies on field. Our aim is to assess the screening execution, HCV prevalence, and DAAs treatment among incarcerated women. A focused insight on quick vs standard diagnosis and staging approach will be also provided.

Methods: Incarcerated women from 4 Italian regions’ penitentiary institutes were included. HCV screening was executed with HCV saliva test (QuickOral Test®) or phlebotomy. Stage of liver fibrosis was evaluated with FIB-4 value or fibroscan®, based on physicians’ decision. Treatment prescription followed national protocols.

Results: We included 156 women, 89 (57%) were Italian, mean age was 41 ± 10 years, and 28 (17.9%) were people who inject drugs (PWIDs). Overall, the HCV seroprevalence was 20.5%. Being PWID and on opioid substitution therapy (OST) were significantly associated with serological status (p-value < 0.001). Of them, the 75.5% of patients had active infection, the most frequent genotype was 3a (50%). Among them, 4 (16.6%) and 6 (25%) had psychosis or alcohol abuse history. The 62.5%, 25% and 12.5% had low, intermediate, and advanced fibrosis, respectively. Out of the 24 HCV-RNA positive patients, the 75% underwent to DAAs treatment. The sustained virological response (SVR12) was achieved in 88.8% of cases. When evaluating the influence of quick diagnosis and staging methods vs standard phlebotomy and fibroscan® on SVR12, FIB-4 use showed higher performance for retainment in treatment during prison staying (p = 0.015), while the use of quick saliva test had no influence on the outcome (p = 0.22).

Conclusion: HCV seroprevalence and active infections are very high among incarcerated women. More tailored interventions should be focused on HCV diagnosis and treatment in female prison population. The use of quick staging methods (FIB-4) is useful to increase SVR12 achievement without delays caused by the fibroscan® awaiting.

*Correspondence: vitofiore30010516@gmail.com

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Hepatitis C virus (HCV) infection is more frequent among incarcerated people than general population [1]. The high-risk for HCV transmission makes incarcerated people a very important target population for creating specific HCV micro-elimination pathways [2]. In the direct acting antivirals (DAAs) era, the short schedules and the low risk of adverse reactions increased the number of treatments among HCV infected patients. For these reasons, numerous papers have been published on the feasibility and efficacy of HCV therapy in prison settings. Furthermore, literature on updates in HCV epidemiology and cascade of care in penitentiary settings is rising in the last years [3, 4].

Previous data from the Italian Ministry of Health highlighted how incarcerated women were twice more likely than incarcerated men and 14 times than the general population to have HCV infection [5].

Data from the Ministry of Justice show how incarceration among women is highly related to sex work and drugs, very often related to each other [6]. This makes female incarcerated population at high-risk for blood-borne viruses.

As per law from February 2020, the Italian Ministry of health allocated a specific fund for the introduction of free HCV screening for the unaware identification among specific subpopulations, such as incarcerated people and people who inject drugs (PWIDs) [7]. The objective is the HCV elimination, according to 2030 WHO targets, with a quick linkage to care in those specific settings.

Although the current national literature highlights how current micro-eradication strategies and new drugs could lead to similar results both in penitentiary settings and outside community, all available literature is concordant in defining incarcerated women as the harder-to-reach population [3, 8–10].

As of November 2020, out of 54,368 daily incarcerated people, 2303 (4.2%) were women, according to Ministry of Justice data [6].

Till now, there are no clear national data on screening execution, HCV prevalence reassessment, and DAAs treatment among incarcerated women.

Our study aims to describe the current HCV prevalence, active infection rates, clinical features, and the efficacy of direct acting antivirals (DAAs) among Italian incarcerated women. A focused insight on quick vs standard diagnosis and staging approach will be also provided.

Patients and methods

Patients’ definition

We consecutively enrolled incarcerated women from 4 Italian regions. The inclusion criteria were adult age (≥ 18 years old) and informed consent signing. Patients with previously known HCV screening were excluded. PWIDs, alcohol dependence, and psychiatric disorders were defined based on the dedicated psychiatric and dependency service, available in all Italian penitentiary institutes.

The tests offer

HCV screening was executed with HCV saliva test (QuickOral Test®) or phlebotomy, based on availability or adherence to the SIMSPe micro-elimination project [3].

The screening tests were offered at prison admission (if quick tests, directly performed by the Specialists with dedicated nurses). Patients testing positive to QuickOral Test® subsequently underwent blood testing for HCV-RNA (Siemens®), genotype, HIV, and HBV screenings. Patients performing phlebotomy had to wait the laboratory results before staging.

Liver fibrosis evaluation

Liver fibrosis was evaluated with FIB-4 value [11] or fibroscan®, based on physicians’ decision. Fibroscan® was programmed on territorial services. Patients with FIB-4 value > 3.25 and/or METAVIR F4 according to fibroscan® underwent liver ultrasound to exclude hepatocellular carcinoma suspicion.

Treatment prescription and delivery

Treatment prescription was telematical and regardless of liver stage of fibrosis, as per national protocols [12]. DAAs delivery (glecaprevir/pibrentasvir or sofosbuvir/velpatasvir) was within one week from staging tests availability, and administration was directly observed. Drug choice depended on patients’ characteristics, choice, or drug-drug interactions with chronic therapy.

Linkage-to-care approach

There are no national indications regarding the patients’ length of stay in prison and DAAs prescription. However, to maximize the retainment in care, if the patients were next to release or transfer, they were linked by the Specialist to territorial services (referral centers/methadone
clinics) or in the new penitentiary institute. The linkage-to-care was in charge of the Specialist who offered the screening and staging tests.

Outcomes
Seroprevalence was based on HCV antibodies (HCV-Ab) detection. HCV active infection was defined by HCV-RNA positivity. End of treatment (EOT) was defined as treatment completion. The sustained virological response (SVR12) was defined as HCV-RNA negativity after 12 weeks from the EOT. Virological failure was defined as positive HCV-RNA after EOT negativity. Drop-outs were considered as: unplanned interruptions during treatment or not treatment start, due to unexpected release/transfer or patients’ decision.

Sample size and statistical analysis
Based on female prison population [6], a prevalence up to 10.4% [3], a 0.05 precision and a confidence interval (CI) of 95%, the sample size needed was of 135 patients (CI specified limits 5.4–15.4%). Data distribution was evaluated with Kolgomorov-Smirnov test before analysis. Data were elaborated as numbers on total (percentages), means ± standard deviations (SD), and median (IQR). Categorical variables were evaluated with Chi-squared test or Fishers’ exact test, when appropriate. Logistic regression analysis was carried out to assess the relationship between HCV-Ab positivity/active HCV infection and epidemiological, demographic, and clinical variables, as well as to evaluate the relationship between quick testing and staging with SVR12. A two-tailed p-value less than 0.05 was considered statistically significant. Statistical computations were carried out with the statistical software STATA version 16 (StatsCorp, Texas, USA).

Results
HCV epidemiology
Out of the 190 Italian penitentiary institutes, 5 centers from four Italian regions participated, representing the 10% of female prison population.

From November 2020, 156 incarcerated women were consecutively enrolled. Of them, 89 (57%) were Italian, mean age was 41 ± 10 years, and 28 (17.9%) were PWIDs. Out of the 156 screened women, 134 (85.9%) were screened with HCV saliva test, while the others with phlebotomy.

Overall, 32 (20.5%) tested positive for HCV-Ab. Of them, 24 (75.5%) had positive HCV-RNA. PWIDs represented the most part of active infections (18; 75%).

The most frequent genotype was 3a (12; 50%). Regarding fibrosis evaluation, FIB-4 score was used in 15 (62.5%) cases. The remaining cases were staged with fibroscan®.

The majority of patients (15; 62.5%) had low fibrosis (FIB-4 score < 1.45; METAVIR F0-F1 according to fibroscan®). Among them, 4 (16.6%) and 6 (25%) had psychosis or alcohol abuse history. Baseline characteristics of incarcerated women who tested positive for HCV-RNA have been reported in Table 1.

When evaluating the relationship between HCV-Ab positivity, epidemiological and clinical variables, the logistic regression highlighted a statistically significant association with being PWID and on OST (p-value < 0.001), as reported in Table 2. However, active infection was not influenced by these factors.

When considering patients who tested HCV-Ab positive and HCV-RNA negative (8; 22.2%), 6 (75%) were previously treated with DAAs, and 2 (25%) had spontaneous eradication.

HCV infection among PWIDs, level of awareness, and previous treatments
Evaluation of awareness on serological status did not show significant differences between PWIDs and non-PWIDs [PWIDs vs non-PWIDs = 14 vs 22] (p-value < 0.05). Therefore, logistic regression analysis was carried out to assess the relationship between HCV-Ab positivity and PWIDs, as well as the relationship between quick testing and staging with SVR12. A two-tailed p-value less than 0.05 was considered statistically significant. Statistical computations were carried out with the statistical software STATA version 16 (StatsCorp, Texas, USA).

Table 1 Demographics and clinical characteristics of HCV infected women enrolled in our study

| Variable                                    | Results (n = 24) |
|---------------------------------------------|-----------------|
| Italian nationality, n (%)                  | 17 (70.8)       |
| Age, mean ± SD                              | 41 ± 9.5        |
| PWIDs, n (%)                                | 18 (75)         |
| On OST, n (%)                               | 13/18 (72.2)    |
| Psychosis, n (%)                            | 4 (16.6)        |
| Alcohol abuse, n (%)                        | 6 (25)          |
| HBsAg, n (%)                                | 1 (4.2)         |
| HBeAb, n%                                   | 4 (16.6)        |
| HIV, n (%)                                  | 6 (25)          |
| Median (IQR) HCV RNA value                  | 608,500 (339,575–1,449,312) |
| Genotypes, n (%)                            |                 |
| 1a                                          | 10 (41.6)       |
| 1b                                          | 1 (4.2)         |
| 2                                           | –               |
| 3a                                          | 12 (50)         |
| 4                                           | 1 (4.2)         |
| Fibrosis according to fibroscan® and FIB-4 value*, n (%) |             |
| Low                                         | 15 (62.5)       |
| Intermediate                                | 6 (25)          |
| Advanced                                    | 3 (12.5)        |

IQR interquartile range, PWIDs people who inject drugs, OST opioid substitution therapy, ART anti-retroviral therapy. *Low = METAVIR F0-F1 or FIB-4 < 1.45; Intermediate = METAVIR F2-F3 or FIB-4 between 1.45 and 3.25; Advanced = METAVIR F4 or FIB-4 > 3.25
as well as for active infection ($p$-value = 0.07). No significant differences in awareness were found also when considering only active infections ($p=0.06$). Furthermore, no significant differences were found between PWIDs and non-PWIDs regarding previous DAAs treatments [PWIDs vs non-PWIDs = 4 vs 2 ($p$-value = 0.43)].

### Table 2

|             | Unadjusted |          | Adjusted |          |
|-------------|------------|----------|----------|----------|
|             | OR (95% CI)| $p$-value| OR (95% CI)| $p$-value|
| Italian nationality | 3.3 (1.3–8.3) | 0.009 | 2.2 (0.6–7.9) | 0.21 |
| PWID        | 43.2 (14.3–131.2) | < 0.001 | 20.4 (5.4–76.8) | < 0.001 |
| OST         | 139.4 (17.3–1123.4) | < 0.001 | 47.9 (4.6–495.2) | < 0.001 |
| HIV         | 3.0 (1.0–8.8)  | 0.042 | 3.4 (0.9–12.9) | 0.07 |

PWID person who inject drugs, OST opioid substitution therapy

#### HCV treatment and outcomes

Out of the 24 incarcerated women who tested HCV-RNA positive, 18 (75%) underwent to DAAs treatment. Prescribed drug schedules were 8-week therapy with glecaprevir/pibrentasvir and 12-week sofosbuvir/velpatasvir schedule in 11 (61.1%) and 7 (38.9%) cases, respectively. EOT was reached in 16 (88.8%) cases, and all of them achieved the SVR12. The remaining patients dropped out due to unexpected release to freedom (1; 5.6%) or transfer to another prison (1; 5.6%). The six remaining patients (25%) were released immediately before DAAs prescription but were linked to care in territorial services. HCV cascade of care has been reported in Fig. 1.

#### Quick vs standard approach

When analyzing all the drop-outs (both unplanned interruptions and drop-out after prescription), FIB-4 use showed higher performance for retainment in treatment during prison staying ($p=0.015$), while the use of quick saliva test had no influences on the outcome ($p=0.22$). Logistic regression aiming to evaluate the relationship
between SVR12 and quick screening and staging methods has been reported in Table 3.

**Discussion**

This is the largest HCV survey among incarcerated women ever conducted in Italy. Incarcerated women are one of the harder-to-reach populations. In Italian penitentiary institutes, <5% of incarcerated people are female. The limited women inclusion is one of the biggest limitations in the most part of the studies on prison settings [3, 8–10]. As consequence, the Specialist activity to reach them out should be pro-active.

We found a HCV seroprevalence of 20.5%, which is slightly higher than the prevalence reported in the more recent literature in field. In fact, the most recent studies show a HCV-Ab prevalence <15% [3, 4]. Moreover, the most part of included patients were surprisingly viremic. This highlights the necessity of better targeted interventions on female prison population.

Mainly, patients had a low liver fibrosis, datum concordant with the low mean age of included women, and with the previous literature in field [3, 4].

As part of our results, HCV-Ab positivity was related to being PWID and OST, but active infection had not relationships with demographical and clinical features. Furthermore, level of awareness was not statistically different between PWIDs and non-PWIDs. This is divergent from our previous data [3]. However, the sample of both HCV-Ab positive and chronically infected patients was small, and this could have influenced the analysis.

High SVR12 rates were reached (~90%). The patients undergoing to quick staging methods (FIB-4) were more likely to achieve SVR12 than people undergoing fibroscan®. This could be related to the reduced delays when compared with fibroscan® awaiting, with less possibility of unplanned interruptions due to unexpected prison release or transfer. Surprisingly, there was no difference between saliva quick test execution and phlebotomy. However, data came from penitentiary institutes where the HCV testing is offered in routine clinical practice at prison admission. This can represent a bias, making this result not necessarily applicable to the whole national context. In fact, the better performance of an approach based on a step-by-step model of quick screening and fast-track staging and treatment in prison micro-environments has been well described by literature [3]. HCV point-of-care testing with quick tests has been widely recognized as a feasible screening method, which gives the possibility of HCV diagnosis among underserved populations, such as incarcerated people [13–15]. The use of quick applicable scores (FIB-4) instead of instrumental staging, was in line with these data.

Given the difference in terms of SVR12, it seems the accessibility to fibroscan® has been overcome by the other indirect staging methods, with a quicker DAAs prescription. Despite this, Italian penitentiary institutes are still not homogeneous in the diagnostic and therapeutic paths. Prison settings are an extraordinary occasion for an extensive approach to HCV fast-track test, staging, and treatment. Targeted interventions should be improved for these settings [16]. Furthermore, the possibility of a directly observed treatment is an added value for creating better micro-elimination pathways [17–19]. A high advantage was represented by the linkage-to-care on territorial services. This kind of approach is increasingly being used nationwide, allowing to maintain in care the patients, even after release.

In conclusion, to increase HCV prevention and a quick test, staging and treatment strategy is highly beneficial in prison settings, as well described by literature [20, 21]. Incarcerated women are a minority of Italian prison settings populations, with higher difficulties to reach them without specific programs. A gender specific network would be useful to increase the retainment in care of this subgroup.

**Clinical risk management and medicolegal aspects.**

The Italian law n. 24 of 2017 recognizes the health of citizens as a constitutionally guaranteed right, also through the objective the safety of care to be guaranteed in every health activity [22]. This right is ensured through the implementation of clinical risk management and prevention activities in every healthcare setting, either hospital or territorial.

The penitentiary administration has custody of people deprived of personal liberty. As consequence, it should provide health services thorough the National healthcare system. Moreover, the rights of restricted citizens cannot be less considered than those of free citizens. A general analysis of the system makes it possible to appreciate how the same health management problems exist in the prison world as global health systems for free citizens, with further difficulties represented by the criticality of identification, acquisition and interpretation of the performance and safety indicators of the patient [23].

### Table 3 Logistic regression carried out to assess the relationship between SVR12 and quick screening and staging methods among incarcerated women with HCV infection included in our study

|          | Unadjusted |          | Adjusted |          |
|----------|------------|----------|----------|----------|
|          | OR (95% CI)| p-value  | OR (95% CI)| p-value  |
| FIB-4    | 13 (1.7–99.4) | 0.013    | 19.5 (1.8–214.6) | 0.015    |
| Quick saliva test | 2.2 (0.3850–12.6) | 0.37    | 4.5 (0.4–51.6) | 0.22    |
The diagnostic-therapeutic pathways guaranteed inside the penitentiary system may encounter obstacles. For this reason, optimal counselling on blood-borne viruses and the creation of simplified microelimination pathways is fundamental.

In conclusion, our survey shows how the opportunity to test and treat viral hepatitis in prison settings is useful not only from a clinical and diagnostic point of view, but also in medical-legal terms and—strategically—in terms of prevention risk.

Limitations of the study
Some limitations should be addressed regarding our study. First of all, our data came only from voluntary self-included penitentiary institutes, which represent a minority of the whole female incarcerated population. For this reason, our results may not reflect the whole national situation. Furthermore, screening and staging methods were not homogeneous in all centers. This may represent an important bias of the study. A limited number of clinical variables were included in our analysis, as well as a small patients’ sample. More institutional coordination is needed in order to create common point of view and strategies. Regarding the screened and staged patients who did not start DAAs during prison stay, they were linked to territorial services, but we do not have data on their treatment. A better national network development, involving Ministry of Justice, Health, methadone clinics, and General Practitioners would allow to better evaluate the treatment success after release.

Acknowledgements
Not applicable.

Author contributions
VF and ER conceived the study. VF, ER, RR, ADV, RG, GDM, AMI, and SDI organized database. VF and ADV performed data analysis. GM, GS, and SB supervised the study conduct. VF, ER, GDM and MB contributed to original draft preparation. All authors contributed to manuscripts’ review and editing. All authors have read and agreed to the published version of the manuscript. All authors read and approved the final manuscript.

Funding
No funds, grants, or other support were received.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Our study was conducted in accordance with the Declaration of Helsinki. All patients signed an informed consent before participating. Data were fully anonymized. Our protocol was approved by Ethics Committee of Istituto Supremo di Sanità, Roma, Italy -PRE BIO CE n. 38/626, req. 27/11/2018.

Consent to publication
Not applicable.

Competing interests
The authors have no conflict of interest to declare.

Author details
1 Infectious and Tropical Disease Clinic, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 35/b, 07100 Sassari, Italy.
2 Medicina Pro(et)ta-Unit of Infectious Diseases, Belcolle Hospital, Viterbo, Italy.
3 Penitentiary Infectious Diseases Unit, A.O. Santi Paolo e Carlo, University of Milan, Milan, Italy.
4 Forensic Medicine, Department of Law, Magna Graecia, University of Catanzaro, Catanzaro, Italy.
5 Legal Medicine, University of Padua, 35121 Padova, Italy.
6 Health Protection for Adults and Youth Unit, Penitentiary Institute, Salerno, Italy.

Received: 22 November 2021 Accepted: 23 June 2022
Published online: 07 July 2022

References
1 Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013;58:1215–24.
2 Rich JD, Allen SA, Williams BA. Responding to hepatitis C through the criminal justice system. N Engl J Med. 2014;370:1871–4.
3 Fiore V, De Matteis G, Ranieri R, Saderi L, Pontali E, Muredda A, et al. HCV testing and treatment initiation in an Italian prison setting: a step-by-step model to micro-eliminate hepatitis C. Int J Drug Policy. 2021;90: 103055.
4 Masarone M, Caruso R, Aglioti A, Izzo C, De Matteis G, Attanese MR, et al. Hepatitis C virus infection in jail: difficult-to-reach, not to-treat. Results of a point-of-care screening and treatment program. Dig Liver Dis. 2020;52:541–6.
5 University of Turin. Progetto I.Ri.D.E 2: Una ricerca intervento per definire, confrontare e valutare modelli di intervento efficaci e trasferibili di riduzione del danno e dei rischi di trasmissione di HIV nella popolazione carcerearia. 2016 Nov 26. https://www.salute.gov.it/imgs/C_17_pagin eAree_200_listaFile_itemName_7_file.pdf. Accessed 2 July 2021.
6 Italian Ministry of Justice. Statistics.https://www.giustizia.it/giustizia/it/img_1_14.page?facetNode=0_2&selectedNode=0_2_10. Accessed 2 July 2021.
7 Italian Ministry of Health. Legge n. 8. Articolo 25 sexies. 2020 Feb 28. https://www.tuttocamereret/files/Archivio1/2020_08.pdf. Accessed 2 July 2021.
8 Fiore V, Ranieri R, Dell’Isola S, Pontali E, Barbarini G, Prestileo T, et al. Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viremic HCV patients: a case-control study. Liver Int. 2021;41:271–5.
9 Pontali E, Fiore V, Ialungo AM, Ranieri R, Mollaretto O, Barbarini G, et al. Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy. Int J Drug Policy. 2018;59:50–3.
10 Fiore V, De Vito A, Pontali E, Lucania L, Mateddu G, Babudieri S. Chronic viral hepatitis in the Italian prison setting: prevalence, outcomes, literature needs and perspectives. Healthcare. 2021;9:1186.
11 Sterling RK, Lissen E, Clumneck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology. 2006;43:1317–25.
12 AIF. Documento di indirizzo dell’Associazione Italiana per lo Studio del Fegato per l’uso razionale dei farmaci anti-HCV disponibili in Italia. 2019. https://www.webais.org/wp-content/uploads/2019/01/documento_hcv_200618.pdf. Accessed 2 July 2021.
13 Beckwith CG, Kurth AE, Bazermax L, Solomon L, Patry E, Rich JD, et al. Survey of US correctional institutions for routine HCV testing. Am J Public Health. 2015;105:68–71.
14 Bottero J, Boyd A, Gzian J, Carrat F, Nau J, Pauti MD, et al. Simultaneous human immunodeficiency virus-hepatitis B-hepatitis C point-of-care tests improve outcomes in linkage-to-care: results of a randomized control trial in persons without healthcare coverage. Open Forum Infect Dis. 2015;2:cof162.
15 Candfield S, Samuel Mi, Ritchie D, McDonald C, Brady M, Taylor C. Use and acceptability of salivary hepatitis C virus testing in an English Young Offender Institution. Int J STD AIDS. 2017;28:1234–8.
16. Ranieri R, Starmini G, Carbonara S, Pontali E, Leo G, Romano A, et al. Management of HCV infection in the penitentiary setting in the direct-acting antivirals era: practical recommendations from an expert panel. Infection. 2017;45:131–8.

17. Schmidbauer C, Schubert R, Schütz A, Schwanke C, Luhn J, Gusic E, et al. Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs—first real world data from Austria. PLoS ONE. 2020;15: e0229239.

18. Gallelli L, Staltari O, Palleria C, Di Mizio G, De Sarro G, Caroleo B. A case of adverse drug reaction induced by dispensing error. J Forensic Leg Med. 2012;19:497–8.

19. Coffin PO, Santos GM, Behar E, Herr J, Walker J, Matheson T, et al. Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs. PLoS ONE. 2019;14: e0217471.

20. Cuadrado A, Lerena S, Cobos C, Pallás JR, Mateo M, Cabezas J, et al. Microenvironment eradication of hepatitis C: a novel treatment paradigm. Am J Gastroenterol. 2018;113:1639–48.

21. Akiyama MJ, Kronfli N, Cabezas J, Sheehan Y, Thurairajah PH, Lines R, et al. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework. Lancet Gastroenterol Hepatol. 2021;6:391–400.

22. Bellandi T, Tartaglia R, Sheikh A, Donaldson L. Italy recognises patient safety as a fundamental right. BMJ. 2017;357: j2277.

23. Bolcato M, Russo M, Rodriguez D, Aprile A. Patient blood management implementation in light of new Italian laws on patient’s safety. Transfus Apher Sci. 2020;59: 102811.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.